Evidence map›Paper›PMID 39267673›Full record

ArticleAmerican journal of cancer research2024

PCMT1 confirmed as a pan-cancer immune biomarker and a contributor to breast cancer metastasis.

Yiqi Liu, Haobing Li, Xiangyu Shen, Ying Liu, Xiaoxiao Zhong, Jing Zhong, Renxian Cao

Abstract read
In one paragraph

Article in American journal of cancer research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yiqi LiuThe First Affiliated Hospital, Hengyang Medical School, University of South China Hengyang 421001, Hunan, China.
Haobing LiInstitute of Clinical Medicine, The First Affiliated Hospital, Hengyang Medical School, University of South China Hengyang 421200, Hunan, China.
Xiangyu ShenDepartment of Breast and Thyroid Surgery, Third Xiangya Hospital, Central South University Changsha 410000, Hunan, China.
Ying LiuInstitute of Clinical Medicine, The First Affiliated Hospital, Hengyang Medical School, University of South China Hengyang 421200, Hunan, China.
Xiaoxiao ZhongDepartment of Breast and Thyroid Surgery, Third Xiangya Hospital, Central South University Changsha 410000, Hunan, China.
Jing ZhongInstitute of Clinical Medicine, The First Affiliated Hospital, Hengyang Medical School, University of South China Hengyang 421200, Hunan, China.
Renxian CaoInstitute of Clinical Medicine, The First Affiliated Hospital, Hengyang Medical School, University of South China Hengyang 421200, Hunan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Protein L-isoaspartyl (D-aspartyl) methyltransferase (PIMT, gene name PCMT1) is an enzyme that repairs proteins with altered aspartate residues by methylation, restoring their normal structure and function. This study conducted a comprehensive analysis of PCMT1 in pan-cancer. The Cancer Genome Atlas, Human Protein Atlas website, and the Genotype-Tissue Expression were utilized in analysis of PCMT1 expression. We examined the association between PCMT1 expression and various factors, including gene modifications, DNA methylation, immune cell infiltration, immunological checkpoints, drug susceptibility, tumor mutation burden (TMB), and microsatellite instability (MSI). Enrichment analyses determined the potential biological roles and pathways involving PCMT1. Our focus then shifted to the role of PCMT1 in breast invasive carcinoma (BRCA). We found that PCMT1 expression was aberrant in many tumors and significantly influenced the prognosis across several cancer types. Gene alterations in PCMT1 predominantly involved deep deletions and amplifications. A negative correlation was observed between DNA methylation and PCMT1 expression across all studied cancer types except thyroid carcinoma PCMT1 exhibited positive correlations with common lymphoid progenitor and CD4(+) T helper 2 cells, whereas it was inversely correlated with central and effector memory T cells, memory CD8(+) T cells, and CD4(+) T helper 1 cells. In many cancer types, PCMT1 expression closely correlated with immunological checkpoint inhibitors, TMB, and MSI. It was also significantly linked to pathways involved in epithelial-mesenchymal transition (EMT), highlighting its role in cancer metastasis. PCMT1 emerged as a significant predictor of breast cancer progression. In vitro experiments demonstrated that reducing PCMT1 expression decreased BRCA cell migration and invasiveness. Additionally, animal studies confirmed that inhibition of PCMT1 slowed tumor growth.

Indexed as

breast invasive carcinomaimmune infiltrationpan-cancerPCMT1prognosis biomarker

Identifiers

PMID39267673
PMCPMC11387850

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.